Press Release Biotechnology 1 min read

Allink Biotherapeutics Completes $47M Extension Rounds of Series A to Accelerate Clinical Programs and Novel Platforms Development

Allink Biotherapeutics raised $47 million in Series A extension rounds led by Legend Capital and Meituan Long-Z Investment to advance its clinical-stage ADC and multi-specific antibody programs for oncology and immunology.

Lanchi Ventures Yuanbio Venture Capital 5Y Capital Lapam Capital Runzhang Venture Capital Allink Biotherapeutics Inc.
Press ReleaseDecember 16, 2025
Lanchi Ventures

Allink Biotherapeutics raised $47 million in Series A extension rounds led by Legend Capital and Meituan Long-Z Investment to advance its clinical-stage ADC and multi-specific antibody programs for oncology and immunology.

Related articles

Press ReleaseMay 25, 2026
FinVolution Group

FinVolution Group Announces New Share Repurchase Program of Up to US$150 million

May 25, 2026
Press ReleaseMay 25, 2026
TECO Electric & Machinery Co.

TECO Signs Acquisition Agreement with Malaysia's Dynaciate, Targeting Exponential AIDC Revenue Growth Next Year

May 25, 2026
Press ReleaseMay 25, 2026
EAAA India Alternatives Ltd

Cyient Semiconductors Announces Strategic Financing with Edelweiss at ~ USD 500 Mn. Equity Valuation

May 25, 2026
← Back to all articles

Generated by Olivia 6